135 related articles for article (PubMed ID: 21197550)
21. Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.
Jin Y; An X; Cai YC; Cao Y; Cai XY; Xia Q; Tan YT; Jiang WQ; Shi YX
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1545-51. PubMed ID: 21842218
[TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid treatment at home: safety data from an observational prospective trial.
Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid in metastatic bone disease: an audit based discussion.
Akbar RA; Gosh SK; Khalil S; ul Haq SM
J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
[TBL] [Abstract][Full Text] [Related]
25. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
[TBL] [Abstract][Full Text] [Related]
26. [Effect of the administration of zoledronic acid on life expectancy in patients with multiple myeloma with or without renal impairment].
Morio K; Tsugane M; Mizuki M; Uejima E
Gan To Kagaku Ryoho; 2014 Apr; 41(4):461-5. PubMed ID: 24743361
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
Hatoum HT; Lin SJ; Smith MR; Barghout V; Lipton A
Cancer; 2008 Sep; 113(6):1438-45. PubMed ID: 18720527
[TBL] [Abstract][Full Text] [Related]
28. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.
Yamasaki M; Yuasa T; Uehara S; Fujii Y; Yamamoto S; Masuda H; Fukui I; Yonese J
Int J Clin Oncol; 2016 Dec; 21(6):1191-1195. PubMed ID: 27402103
[TBL] [Abstract][Full Text] [Related]
29. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
[TBL] [Abstract][Full Text] [Related]
30. [Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma].
Koike K; Fukami K; Morishige S; Hazama T; Taguchi K; Ando R; Nagano M; Yoshimura J; Ueda S; Hashiguchi M; Tamaki K; Nishida H; Okuda S
Nihon Jinzo Gakkai Shi; 2009; 51(5):557-62. PubMed ID: 19715164
[TBL] [Abstract][Full Text] [Related]
31. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
Yazici O; Aksoy S; Ucar O; Ozdemir N; Demir M; Sendur MA; Arik Z; Yaman S; Eren T; Uncu D; Zengin N
Med Oncol; 2013; 30(3):609. PubMed ID: 23690271
[TBL] [Abstract][Full Text] [Related]
32. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; MartÃn M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L; Goranitis I; Pirrie S; Pope A; Barton D; Collins S; Daunton A; McLaren D; O'Sullivan JM; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown JE; Chakraborti P; Hussain SA; Russell JM; Billingham LJ; James ND
BJU Int; 2017 Apr; 119(4):522-529. PubMed ID: 27256016
[TBL] [Abstract][Full Text] [Related]
34. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
35. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
39. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
Sheedy KC; Camara MI; Camacho PM
Endocr Pract; 2015 Mar; 21(3):275-9. PubMed ID: 25370317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
